Published in Obesity and Diabetes Week, December 27th, 2004
The University's two human islet cell transplants were an unqualified success. These trials, conducted by the University, are for the use of PHER-O2 in the transportation and transplantation of pancreas islet cells.
A second group of 20 samples of PHER-O2 has recently been delivered to the University.
Thomas Drees, PhD, chairman and chief executive officer of Sanguine Corporation, stated, "...Diabetes is the fastest growing chronic disease in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.